• 1
    Norris KC, Agodoa LY. Unraveling the racial disparities associated with kidney disease. Kidney Int. 2005;68:914924.
  • 2
    Agodoa L. Racial disparities in kidney health: the puzzle to solve. Am J Kidney Dis. 2002;40:13371339.
  • 3
    Agodoa L, Eggers P. Racial and ethnic disparities in end-stage kidney failure: survival paradoxes in African-Americans. Semin Dial. 2007;20:577585.
  • 4
    United States Renal Data System. United States Renal Data System 2006 annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States. Am J Kidney Dis. 2007;49:S1296.
  • 5
    United States Renal Data System. Excerpts from the USRDS 2005 annual data report: atlas of end-stage renal disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Am J Kid Dis. 2006;471:1286.
  • 6
    Kalantar-Zadeh K, Golan E, Shohat T, Streja E, Norris KC, Kopple JD. Survival disparities within American and Israeli dialysis populations: Learning from similarities and distinctions across race and ethnicity. Semin Dial 2010; November [in press], Seminars in Dialysis- 2010; DOI: 10.1111/j.1525-139X.2010.00795.x
  • 7
    Kalantar-Zadeh K, Shah A, Duong U, Hechter RC, Dukkipati R, Kovesdy CP. Kidney bone disease and mortality in CKD: revisiting the role of vitamin D, calcimimetics, alkaline phosphatase, and minerals. Kidney Int Suppl. 2010; Aug; (117): S1021.
  • 8
    Lee GH, Benner D, Regidor DL, Kalantar-Zadeh K. Impact of kidney bone disease and its management on survival of patients on dialysis. J Ren Nutr. 2007;17:3844.
  • 9
    Fadem SZ, Moe SM. Management of chronic kidney disease-mineral bone disorder. Adv Chronic Kidney Dis. 2007;14:2.
  • 10
    Moe SM, Drueke T, Lameire N, Eknoyan G. Chronic kidney disease-mineral-bone disorder: a new paradigm. Adv Chronic Kidney Dis. 2007;14:312.
  • 11
    De Boer IH, Gorodetskaya I, Young B, Hsu CY, Chertow GM. The severity of secondary hyperparathyroidism in chronic renal insufficiency is GFR-dependent, race-dependent, and associated with cardiovascular disease. J Am Soc Nephrol. 2002;13:27622769.
  • 12
    Omije D, Norris K, Wang J, Pan D, Kermah D, Gupta A. Race is a major determinant of secondary hyperparathyroidism in uremic patients: comparative study of Blacks and Hispanics. Clin Nephrol. 2008;70:312318.
  • 13
    Fan SL, Chan A, Raftery MJ, Yaqoob MM. Race and sex: predictors of the severity of hyperparathyroidism in peritoneal dialysis patients. Nephrology (Carlton). 2006;11:1520.
  • 14
    Owda A, Elhwairis H, Narra S, Towery H, Osama S. Secondary hyperparathyroidism in chronic hemodialysis patients: prevalence and race. Ren Fail. 2003;25:595602.
  • 15
    Gupta A, Kallenbach LR, Zasuwa G, Divine GW. Race is a major determinant of secondary hyperparathyroidism in uremic patients. J Am Soc Nephrol. 2000;11:330334.
  • 16
    Wolf M, Betancourt J, Chang Y, et al. Impact of activated vitamin d and race on survival among hemodialysis patients. J Am Soc Nephrol. 2008.
  • 17
    Zigmond J. New dialysis payment plan. Providers worry about effects of bundling payments. Mod Healthc. 2009;39:1011.
  • 18
    Sullivan J. Bundling and its potential impact on dialysis service providers. Nephrol News Issues. 2008;22: 12, 14, 1617.
  • 19
    Coutts LR. Is bundling the solution for managing the cost of care? Nephrol News Issues. 2008;22:11.
  • 20
    Miller JE, Kovesdy CP, Nissenson AR, et al. Association of hemodialysis treatment time and dose with mortality: the role of race and gender. Am J Kidney Dis. 2010;55:100112.
  • 21
    Kalantar-Zadeh K, Lee GH, Miller JE, et al. Predictors of hyporesponsiveness to erythropoiesis-stimulating agents in hemodialysis patients. Am J Kidney Dis. 2009;53:82334.
  • 22
    Kalantar-Zadeh K, Regidor DL, Kovesdy CP, et al. Fluid retention is associated with cardiovascular mortality in patients undergoing long-term hemodialysis. Circulation. 2009;119:671679.
  • 23
    Regidor DL, Kovesdy CP, Mehrotra R, et al. Serum alkaline phosphatase predicts mortality among maintenance hemodialysis patients. J Am Soc Nephrol. 2008;19:21932203.
  • 24
    Shinaberger CS, Greenland S, Kopple JD, et al. Is controlling phosphorus by decreasing dietary protein intake beneficial or harmful in persons with chronic kidney disease? Am J Clin Nutr. 2008;88:15111518.
  • 25
    Shinaberger CS, Kopple JD, Kovesdy CP, et al. Ratio of paricalcitol dosage to serum parathyroid hormone level and survival in maintenance hemodialysis patients. Clin J Am Soc Nephrol. 2008;3:17691776.
  • 26
    Streja E, Kovesdy CP, Greenland S, et al. Erythropoietin, iron depletion, and relative thrombocytosis: a possible explanation for hemoglobin-survival paradox in hemodialysis. Am J Kidney Dis. 2008;52:727736.
  • 27
    Kalantar-Zadeh K, Kilpatrick RD, Kuwae N, et al. Revisiting mortality predictability of serum albumin in the dialysis population: time dependency, longitudinal changes and population-attributable fraction. Nephrol Dial Transplant. 2005;20:18801888.
  • 28
    Kalantar-Zadeh K, Kovesdy CP. Is it worth correcting hyperparathyroidism if hyperphosphatemia and hypocalcemia worsen? A cinacalcet story. Am J Kidney Dis. 2009;53:183188.
  • 29
    Belozeroff V, Goodman WG, Ren L, Kalantar-Zadeh K. Cinacalcet lowers serum alkaline phosphatase in maintenance hemodialysis patients. Clin J Am Soc Nephrol. 2009;4:673679.
  • 30
    National Kidney Foundation I, Kidney Disease-Dialysis Outcome Quality Initiative 2003K/DOQI Clinical Practice Guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42(suppl 2): S1-S202.
  • 31
    U.S. Renal Data System 2008 USRDS 2006 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. In: National Institutes of Health NIoDaDaKD (ed.) USRDS Annual Report. NIH/NIDDK, Bethesda, MD.
  • 32
    Gutierrez OM, Isakova T, Andress DL, Levin A, Wolf M. Prevalence and severity of disordered mineral metabolism in Blacks with chronic kidney disease. Kidney Int. 2008;73:956962.
  • 33
    Harris SS. Vitamin D and African Americans. J Nutr. 2006;136:11261129.
  • 34
    Aloia JF, Talwar SA, Pollack S, Feuerman M, Yeh JK. Optimal vitamin D status and serum parathyroid hormone concentrations in African American women. Am J Clin Nutr. 2006;84:602609.
  • 35
    United States Renal Data System 2005 Excerpts from the USRDS. Annual data report. Am J Kid Dis. 2004;45:S1S280.
  • 36
    Kalantar-Zadeh K, Abbott KC, Kronenberg F, Anker SD, Horwich TB, Fonarow GC. Epidemiology of dialysis patients and heart failure patients. Semin Nephrol. 2006;26:118133.
  • 37
    United States Renal Data System. Annual report and atlas of chronic kidnye disease & end-stage renal disease. USRDS Report. 2009.
  • 38
    United States Renal Data System. US department of public health and human services. Public Health Service, National Institutes of Health, Bethesda. 2002.
  • 39
    [1993] Morbidity and mortality of dialysis. NIH Consens Statement 11(2) 1-33.
  • 40
    Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15:22082218.
  • 41
    Kalantar-Zadeh K, Kuwae N, Regidor DL, et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int. 2006;70:771780.
  • 42
    Schwarz S, Trivedi BK, Kalantar-Zadeh K, Kovesdy CP. Association of disorders in mineral metabolism with progression of chronic kidney disease clin. J Am Soc Neph. 2006;1:825831.
  • 43
    Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med. 2000;342:14781483.
  • 44
    Raggi P, Boulay A, Chasan-Taber S, et al. Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol. 2002;39:695701.
  • 45
    McCullough PA, Agarwal M, Agrawal V. Review article: Risks of coronary artery calcification in chronic kidney disease: do the same rules apply? Nephrology (Carlton). 2009;14:428436.
  • 46
    Shantouf R, Kovesdy CP, Kim Y, et al. Association of serum alkaline phosphatase with coronary artery calcification in maintenance hemodialysis patients. Clin J Am Soc Nephrol. 2009;4:11061114.
  • 47
    Blayney MJ, Pisoni RL, Bragg-Gresham JL, et al. High alkaline phosphatase levels in hemodialysis patients are associated with higher risk of hospitalization and death. Kidney Int. 2008;74:655663.
  • 48
    Kalantar-Zadeh K, Kovesdy CP. Clinical outcomes with active versus nutritional vitamin D compounds in chronic kidney disease. Clin J Am Soc Nephrol. 2009;4:15291539.
  • 49
    Wolfe RA, Ashby VB, Daugirdas JT, Agodoa LY, Jones CA, Port FK, Body size, dose of hemodialysis, and mortality. Am J Kidney Dis. 2000;35:8088.
  • 50
    Port FK, Ashby VB, Dhingra RK, Roys EC, Wolfe RA. Dialysis dose and body mass index are strongly associated with survival in hemodialysis patients. J Am Soc Nephrol. 2002;13:10611066.